Subscribe to Search results

Dr McVerry could not recall giving cryoprecipitate to a patient in Liverpool.

Published on:

Dr McVerry stated he "was encouraged to switch to commercial F8 for two reasons". Availability and reliability of supply, and the general policy to keep an individual patient on one specific product to reduce prevalence of factor antibodies arising

Published on:

The purchase of commercial Factor 8 concentrates was undertaken via the Royal Liverpool Hospital, in part because the district health authority was able to get a better price per unit by buying in bulk, and supplied by the Royal Liverpool's haemophilia ward to Alder Hey.

Published on:

Professor Hay stated that "all patients were treated with whichever material was available. No cohorts were treated with any specific product". He stated insufficient use of cryoprecipitate was used.

Published on:

When Professor Hay arrived in Liverpool he found records to be poor and uninformative and was unable to obtain the results of the tests that had been carried out. He was told by patients that they were informed of HIV positive results by letter.

Published on:

Other documentation arising in the context of litigation suggests that "no specific priority was given to mild haemophiliacs for treatment with NHS product at the time."

Published on:

Information from legal claims relating to other children treated at Alder Hey reveal the appropriate approach to treatment.

Published on:

A child with severe haemophilia was regularly treated at Alder Hey with concentrate, "at least some of it commercial after mid-1983."

Published on:

A child with mild haemophilia had received commercial Factor VIII for a tooth extraction. This treatment "would not seem to be justified."

Published on:

A child born in 1980 (inferentially with severe haemophilia) "received a substantial amount of concentrate, the majority of it being commercial concentrate. The type of concentrate would have been dependant upon availability and treatment was standard." It was said that there was "Nothing atypical about treatment given to this Plaintiff."

Published on:

Another child with mild haemophilia was treated with what appeared to be NHS Factor 8 in late 1982 and commercial Factor 8 between March and July 1983.

Published on:

A patient with mild/moderate haemophilia was treated with concentrates for elective surgery. The notes lacked detail to identify products used but "Dr Martin's statement confirms that no distinction was made at Alder Hey Hospital in terms of which product to prefer" vs what was available.

Published on:

The Sheffield Centre treated its patients with a mix of NHS concentrates and commercial.

Published on:

There was a greater use of NHS concentrates than commercial, although a substantial amount of the latter (and a small amount of cryoprecipitate) was still used.

Published on:

Sheffield Centre switched to heat treated product occurred at the end of May 1984 along with three other centres.

Published on:

The vast majority of treatment was with commercial concentrates, with very little NHS concentrate used. This was likely to have reflected the use of heat-treated concentrates.

Published on:

An article was published in the Lancet regarding two patients treated with Armour heat-treated who developed NANB Hepatitis and a third treated with BPL's small pool heat-treated product..

Published on:

Local meetings with the Inquiry team

Published on:

Dr Mitchell argued "recurrent treatment with blood products is hazardous... The best approach seems to us to be a treatment policy" designed to reduce all the risks associated with blood products and is tailored to the needs of individual patients.

Published on:

Haemophilia B was referred to "Christmas disease" after the name of the first patient whose condition was examined in detail.

Published on: